Cutaneous Lymphoma International Consortium Study of Outcome in Advanced Stages of Mycosis Fungoides and Sézary Syndrome: Effect of Specific Prognostic Markers on Survival and Development of a Prognostic Model.
about
An overview of cutaneous T cell lymphomasSézary Syndrome and Atopic Dermatitis: Comparison of Immunological Aspects and TargetsSystemic therapy for cutaneous T-cell lymphoma: who, when, what, and why?T-cell Lymphoma Epidemiology: the Known and Unknown.T-cell lymphomas, a challenging disease: types, treatments, and future.The role of extracorporeal photopheresis in the management of cutaneous T-cell lymphoma, graft-versus-host disease and organ transplant rejection: a consensus statement update from the UK Photopheresis Society.Genetic rearrangements result in altered gene expression and novel fusion transcripts in Sézary syndromeCutaneous T-Cell Lymphoma: A Review with a Focus on Targeted Agents.CD30+ Cutaneous T Cell Lymphoma: Response to Rotational Total Skin Electron Irradiation.TP53 Gene Status Affects Survival in Advanced Mycosis Fungoides.Management Strategies for Mycosis Fungoides in India.Malignant inflammation in cutaneous T-cell lymphoma-a hostile takeoverInvestigating potential exogenous tumor initiating and promoting factors for Cutaneous T-Cell Lymphomas (CTCL), a rare skin malignancyBrentuximab vedotin therapy for CD30-positive cutaneous T-cell lymphoma: a targeted approach to management.Multidisciplinary Management of Mycosis Fungoides/Sézary Syndrome.Comprehensive analysis of cutaneous T-cell lymphoma (CTCL) incidence and mortality in Canada reveals changing trends and geographic clustering for this malignancy.Langerhans, plasmacytoid dendritic and myeloid-derived suppressor cell levels in mycosis fungoides vary according to the stage of the disease.The biomarker landscape in mycosis fungoides and Sézary syndrome.Forodesine in the treatment of cutaneous T-cell lymphoma.Aberrant microRNA expression in tumor mycosis fungoides.Brentuximab vedotin in CD30+ cutaneous lymphoma: How do we treat - How shall we treat? A review of the literature.The role of polymorphism of interleukin-2, -10, -13 and TNF-α genes in cutaneous T-cell lymphoma pathogenesis.Gene expression analysis in Cutaneous T-Cell Lymphomas (CTCL) highlights disease heterogeneity and potential diagnostic and prognostic indicators.TruSeq-Based Gene Expression Analysis of Formalin-Fixed Paraffin-Embedded (FFPE) Cutaneous T-Cell Lymphoma Samples: Subgroup Analysis Results and Elucidation of Biases from FFPE Sample Processing on the TruSeq Platform.ONC201 selectively induces apoptosis in cutaneous T-cell lymphoma cells via activating pro-apoptotic integrated stress response and inactivating JAK/STAT and NF-κB pathways.Results from a Phase I/II Open-Label, Dose-Finding Study of Pralatrexate and Oral Bexarotene in Patients with Relapsed/Refractory Cutaneous T-cell Lymphoma.Expression of FK506-binding protein 51 (FKBP51) in Mycosis fungoides.Validation of cutaneous lymphoma international prognostic index (CLIPI) for mycosis fungoides and Sézary syndrome.Global patterns of care in advanced stage mycosis fungoides/Sezary syndrome: a multicenter retrospective follow-up study from the Cutaneous Lymphoma International Consortium.Hypopigmented Mycosis Fungoides with Large Cell Transformation in a Child.Prognostic factors in mycosis fungoides: international advances in the validation of prognostic indices.Transformation of Mycosis Fungoides/Sezary Syndrome: Clinical Characteristics and Prognosis.Prognostic indicators for mycosis fungoides in a Greek population.[Treatment of mycosis fungoides and Sézary syndrome].Cutaneous CD8+ Cytotoxic T-Cell Lymphoma Infiltrates: Clinicopathological Correlation and Outcome of 35 Cases.
P2860
Q26740306-0D67FC1D-FC41-409A-9E59-964B5563B481Q26746551-6973D2BE-F5F2-41CA-8779-F1824B210824Q30239965-971F9C42-100B-4700-8C26-86FAB1420F5AQ30239985-31D63D9E-2201-48E1-87A5-066366B15DBCQ30244553-01730D2B-F16C-40C6-9D4E-1A8C8F41DED3Q33625948-EA27D8BF-EA9A-4B8B-9B23-5261028AEB7EQ33889309-278BF086-8EB6-41CA-8908-BF0F45F24245Q34516083-42ECFBFD-5B16-4719-A8A5-5C6DF2961473Q36999986-7A968707-DC99-4F8F-B713-1D2D07410613Q37407941-DDC50301-1CA0-4C19-B05B-F3FBF36EC711Q37717711-690AF53B-A1B6-47F0-B3D0-7DC22F9F8BBDQ37723390-93D2A7B4-1378-4548-A978-08712E2B306CQ37835711-6287638B-E9B9-494B-A8E5-73FFD9351918Q38643068-7AA0CF37-4148-46B8-81C3-92F029CF07A2Q38765889-F89A6869-1DB9-461B-8516-CD64ADC3127BQ38792428-ACF324A2-6127-46D3-BDFF-9ADA90C95F49Q38892071-4491647E-8617-4D2F-B71A-3F6590C9ED1CQ39023382-54649CB1-912D-4EEA-A9C3-1C05153F4D7DQ39266443-4677F3A1-F27E-41E7-BB0D-E0CC8BB65773Q39395267-165804A3-3446-4700-AE40-D81AA964AD1FQ39432325-5E981D50-E287-4C58-A8DD-224D9C0690CAQ39832921-87E9E256-D8C7-4C63-899A-C71FC06470F9Q40150337-4FD52FCE-C029-41AE-AD18-491E8530F1FAQ42270898-EEC03106-81D6-497D-B7CF-62377093C536Q42365296-CABC52C3-8574-423E-AC77-2B4AA4D642FBQ46006814-68D0C75F-B505-4068-B78C-7A418396AF14Q47699242-1BAE2CC2-500B-45E1-A7D8-32A71CF4B6F9Q47818116-EDEFE081-17C5-413F-8CC3-BEF7CCDF76A4Q47898250-BC9D4AC3-3805-463F-9257-1AA1936A3735Q48246981-8BC511B0-14C7-4F21-AB44-F08B14FE737DQ48650197-526AD439-A9A9-4067-8705-DBD90A38D788Q50630512-9FE624C3-6F84-4257-A464-6A11FD07FFA6Q53039521-56F8A099-537E-41EE-9BCA-8F73CD02548FQ53128681-A0B4CD48-C240-46E7-8414-F75179DE3AC0Q54255260-62E767D5-6477-4656-A6FD-D449D499309B
P2860
Cutaneous Lymphoma International Consortium Study of Outcome in Advanced Stages of Mycosis Fungoides and Sézary Syndrome: Effect of Specific Prognostic Markers on Survival and Development of a Prognostic Model.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 05 October 2015
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Cutaneous Lymphoma Internation ...... lopment of a Prognostic Model.
@en
Cutaneous Lymphoma Internation ...... lopment of a Prognostic Model.
@nl
type
label
Cutaneous Lymphoma Internation ...... lopment of a Prognostic Model.
@en
Cutaneous Lymphoma Internation ...... lopment of a Prognostic Model.
@nl
prefLabel
Cutaneous Lymphoma Internation ...... lopment of a Prognostic Model.
@en
Cutaneous Lymphoma Internation ...... lopment of a Prognostic Model.
@nl
P2093
P2860
P50
P356
P1476
Cutaneous Lymphoma Internation ...... lopment of a Prognostic Model.
@en
P2093
Alain Rook
Alessandro Pileri
Annalisa Patrizi
Anne Pham-Ledard
Christiane Querfeld
Christina Antoniou
Cristina Muniesa
Denis Miyashiro
Dimitis Rigopoulos
P2860
P304
P356
10.1200/JCO.2015.61.7142
P407
P50
P577
2015-10-05T00:00:00Z